Interested individuals should prepare and submit an application to Christine Battle, Publisher and Vice President, Scientific Publications, AACR via email (
[email protected]) by Monday, ...
The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...